echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Lancet Neurol: Levosimendan is expected to improve respiratory failure in amyotrophic lateral sclerosis?

    Lancet Neurol: Levosimendan is expected to improve respiratory failure in amyotrophic lateral sclerosis?

    • Last Update: 2021-11-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com




    The REFALS study is a randomized, double-blind, placebo-controlled phase 3 trial randomized, double-blind, placebo-controlled phase 3 trial
    • Between June 21, 2018 and June 28, 2019, 871 people were screened for the study , and 496 of them were randomly assigned to levosimendan (n=329) or placebo (n=167)


      In the majority of patients with amyotrophic lateral sclerosis, levosimendan is not superior to placebo in maintaining respiratory function


      Cudkowicz M, Genge A, Maragakis N, et al.




      Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.